Movement Alert｜BeiGene Falls 3.02% in Regular Trading, Senior Executive Stake Reduction Combined with Prolonged Innovative Drug Sector Correction

Market Focus06-03

On June 3, BeiGene fell 3.02% in regular trading, trading at HK$163.8/share, with trading volume of approximately HK$291 million.

On the news front, BeiGene recently faced a significant stake reduction by Baker Bros. Advisors LP, a fund affiliated with board directors Julian and Felix Baker, totaling approximately US$190 million. While the fund retains board seats and still holds approximately 8.21% of shares, the sell-off continues to weigh on market sentiment. The reduction was executed at US$260 per ADS when the stock was near its 52-week high, raising concerns over valuation sustainability amid potential competitive threats from Eli Lilly's third-generation BTK inhibitor Pirtobrutinib.

Additionally, the Hong Kong-listed innovative drug sector has been in a correction phase for over eight months since September last year, with the sector benchmark index declining more than 30%. The broader biotech sector weakened today, with Akeso down 4.69%, 3SBio down 3.56%, Innovent Biologics down 2.92%, and Everest Medicines down 3.3%, dragging BeiGene as a heavyweight sector leader.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1140426890?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-03 10:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140426890","market":"us","top_or_hot":-1,"title":"Movement Alert｜BeiGene Falls 3.02% in Regular Trading, Senior Executive Stake Reduction Combined with Prolonged Innovative Drug Sector Correction","media":"Market Focus","content":"<p><p>On June 3, BeiGene fell 3.02% in regular trading, trading at HK$163.8/share, with trading volume of approximately HK$291 million.</p><p>On the news front, BeiGene recently faced a significant stake reduction by Baker Bros. Advisors LP, a fund affiliated with board directors Julian and Felix Baker, totaling approximately US$190 million. While the fund retains board seats and still holds approximately 8.21% of shares, the sell-off continues to weigh on market sentiment. The reduction was executed at US$260 per ADS when the stock was near its 52-week high, raising concerns over valuation sustainability amid potential competitive threats from Eli Lilly's third-generation BTK inhibitor Pirtobrutinib.</p><p>Additionally, the Hong Kong-listed innovative drug sector has been in a correction phase for over eight months since September last year, with the sector benchmark index declining more than 30%. The broader biotech sector weakened today, with Akeso down 4.69%, 3SBio down 3.56%, Innovent Biologics down 2.92%, and Everest Medicines down 3.3%, dragging BeiGene as a heavyweight sector leader.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜BeiGene Falls 3.02% in Regular Trading, Senior Executive Stake Reduction Combined with Prolonged Innovative Drug Sector Correction</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜BeiGene Falls 3.02% in Regular Trading, Senior Executive Stake Reduction Combined with Prolonged Innovative Drug Sector Correction\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-03 10:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 3, BeiGene fell 3.02% in regular trading, trading at HK$163.8/share, with trading volume of approximately HK$291 million.</p><p>On the news front, BeiGene recently faced a significant stake reduction by Baker Bros. Advisors LP, a fund affiliated with board directors Julian and Felix Baker, totaling approximately US$190 million. While the fund retains board seats and still holds approximately 8.21% of shares, the sell-off continues to weigh on market sentiment. The reduction was executed at US$260 per ADS when the stock was near its 52-week high, raising concerns over valuation sustainability amid potential competitive threats from Eli Lilly's third-generation BTK inhibitor Pirtobrutinib.</p><p>Additionally, the Hong Kong-listed innovative drug sector has been in a correction phase for over eight months since September last year, with the sector benchmark index declining more than 30%. The broader biotech sector weakened today, with Akeso down 4.69%, 3SBio down 3.56%, Innovent Biologics down 2.92%, and Everest Medicines down 3.3%, dragging BeiGene as a heavyweight sector leader.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06160","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1140426890","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140426890","pubTimestamp":1780454349,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 3, BeiGene fell 3.02% in regular trading, trading at HK$163.8/share, with trading volume of approximately HK$291 million.On the news front, BeiGene recently faced a significant stake...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06160":"百济神州"},"translate_title":"动向提示|百济神州常规交易跌3.02%高管减持叠加创新药板块回调旷日持久","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1},"content_text":"On June 3, BeiGene fell 3.02% in regular trading, trading at HK$163.8/share, with trading volume of approximately HK$291 million.On the news front, BeiGene recently faced a significant stake reduction by Baker Bros. Advisors LP, a fund affiliated with board directors Julian and Felix Baker, totaling approximately US$190 million. While the fund retains board seats and still holds approximately 8.21% of shares, the sell-off continues to weigh on market sentiment. The reduction was executed at US$260 per ADS when the stock was near its 52-week high, raising concerns over valuation sustainability amid potential competitive threats from Eli Lilly's third-generation BTK inhibitor Pirtobrutinib.Additionally, the Hong Kong-listed innovative drug sector has been in a correction phase for over eight months since September last year, with the sector benchmark index declining more than 30%. The broader biotech sector weakened today, with Akeso down 4.69%, 3SBio down 3.56%, Innovent Biologics down 2.92%, and Everest Medicines down 3.3%, dragging BeiGene as a heavyweight sector leader.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1140426890","isCrawlerRequest":true}